Table 3.
Best responses and overall survival after a median follow-up of 32 months (ITT population)
| HES (n = 12) | CEL (n = 4) | Total (N = 16) | |
|---|---|---|---|
| Best hematologic response | |||
| Overall response, n (%; 95 % CI) | 1 (8.3; 0.2–38.5) | 2 (50.0; 6.8–93.2) | 3 (18.8; 4.0–45.6) |
| CR | 1 (8.3) | 2 (50.0) | 3 (18.8) |
| PR | 0 | 0 | 0 |
| Absence of response, n (%) | 11 (91.7) | 2 (50.0) | 13 (81.3) |
| SD | 3 (25.0) | 1 (25.0) | 4 (25.0) |
| PD | 3 (25.0) | 0 | 3 (18.8) |
| NE | 5 (41.7) | 1 (25.0) | 6 (37.5) |
| Overall survival, % (95 % CI) | |||
| 6 months | 83.3 (62.3–100) | 100 (100–100) | 87.5 (71.3–100) |
| 12 months | 75.0 (50.5–99.5) | 100 (100–100) | 81.3 (62.1–100) |
| 18 months | 75.0 (55.5–99.5) | 100 (100–100) | 81.3 (62.1–100) |
| 24 months | 75.0 (50.5–99.5) | 100 (100–100) | 81.3 (62.1–100) |
CEL chronic eosinophilic leukemia, CHR complete hematologic response, HES hypereosinophilic syndrome, ITT intention to treat, NE not evaluable, PD progressive disease, PHR partial hematologic response, SD stable disease